About this document
Emicizumab Efficacy in Infants with Hemophilia A by Erick Javier Guzman Serrano is a document available to read on EtoBox.
The HAVEN 7 study demonstrates that emicizumab is safe and effective for infants with severe hemophilia A without factor VIII inhibitors, significantly reducing the need for intravenous FVIII and associated risks. The study reported a low annualized treated bleed rate and no new safety signals, but emphasizes the need for longer-term follow-up to assess potential issues such as antibody development and injection-site reactions. Additionally, recent research highlights the role of T cells in acquired aplasti
- Author
- Erick Javier Guzman Serrano
- Language
- EN